9th Annual Proteins and Antibodies Congress 2016 London

• Michel Awwad – Merrimack
• Frank Comer – MedImmune
• Tapan Das – BMS
• Rakesh Dixit – Bio­log­ics Safety Assess­ment, MedImmune
• Per-​Ola Freskgard – Neu­ro­science, Roche Inno­va­tion Cen­ter Basel
• Rajiv Gan­gurde – Pro­tein Pro­duc­tion, Geno­cea Biosciences
• Chang­shou Gao – Depart­ment of Anti­body Dis­cov­ery & Pro­tein Engi­neer­ing, Med­Im­mune LLc
• Steve Hall – Pfizer Reg­u­la­tory Strat­egy, Pfizer World­wide Research and Development

• Haruki Hasegawa – Ther­a­peu­tic Dis­cov­ery, Amgen
• Guna Kan­nan – Amgen
• Bernardo Perez-​Ramirez – Genzyme
• Bianka Prinz – Adimab
• Yang Shen – Eli Lilly
• Binesh Shrestha – Novartis
• Annelise Vuide­pot – Pro­tein Sci­ence, Immunocore
• Mark Wil­son – Down­stream Devel­op­ment, Novar­tis Vac­cines and Diagnostics

Day One will explore Anti­body Dis­cov­ery & Engi­neer­ing, and Pro­tein Expres­sion & Char­ac­ter­i­sa­tion top­ics. New to the anti­bod­ies pro­gramme this year will be a focus on novel anti­body for­mats and immuno-​oncology. Immuno-​oncology is poised to become one of the most impor­tant ther­a­peu­tic areas in the anti­bod­ies field, with many large phar­ma­ceu­ti­cal com­pa­nies launch­ing major col­lab­o­ra­tions in this space this year. Our panel of expert anti­bod­ies speak­ers will dis­cuss the press­ing sci­en­tific and strate­gic con­cerns of immuno-​oncology, includ­ing tar­get iden­ti­fi­ca­tion strate­gies, over­com­ing safety issues, the impact of check point inhibitors and bis­pecifics. Our Pro­tein Expres­sion speak­ers will be explor­ing the lat­est tools for mem­brane pro­tein expres­sion and mol­e­cule design strate­gies to enhance devel­opa­bil­ity. We will also have key academic-​led pre­sen­ta­tions to update del­e­gates about advances in pro­tein sci­ence includ­ing fold­ing, path­way engi­neer­ing and pro­tein modification.

Day 1 Stream 1 – Anti­body Dis­cov­ery & Engineering

• Mov­ing beyond mAbs: novel bis­pe­cific for­mats and ADCs
• Novel ADC pay­loads and con­ju­ga­tion techniques
• Anti­body phar­ma­co­ki­net­ics (PK) and Phar­ma­co­dy­nam­ics (PD)
• New anti­body dis­cov­ery platforms
• Sin­gle domain and recom­bi­nant anti­body tools

Day 1 Stream 2 – Pro­tein Expres­sion & Characterisation

• Emerg­ing tech­nolo­gies for pro­tein expres­sion: imag­ing tools, nan­odiscs and NMR
• Mem­brane pro­teins as key drug tar­gets: over­com­ing purifi­ca­tion and expres­sion hurdles
• The lat­est updates in pro­tein science:
  • pro­teomics
  • fold­ing
  • path­way engineering
  • pro­tein modification
• Design­ing the right pro­teins: com­bat­ting cost of goods with early stage drug design

Day Two will fea­ture high-​level dis­cus­sions about the Ther­a­peu­tic Appli­ca­tions of Anti­bod­ies, includ­ing excit­ing research into the appli­ca­tion of CAR T cell recep­tors in can­cer ther­a­pies and case stud­ies cov­er­ing the lat­est attempts to trans­port anti­bod­ies across the blood-​brain bar­rier. In our Pro­tein Purifi­ca­tion stream del­e­gates will hear about cur­rent efforts to reduce time­lines and cost of goods through auto­mated sys­tems, cell line devel­op­ment and dis­pos­able equip­ment. Del­e­gates will also hear about how large pharma is tack­ling the chal­lenge of pro­tein for­mu­la­tion and ensur­ing sta­bil­ity in phar­ma­ceu­ti­cal manufacturing.

Day 2 Stream 1 – Ther­a­peu­tic Appli­ca­tions of Antibodies

• Novel bis­pe­cific anti­bod­ies and their ther­a­peu­tic potential
• Next-​generation affin­ity reagents: recom­bi­nant and engi­neered anti­bod­ies, nucleic acid aptamers
• Immuno-​oncology: the lat­est research in tar­get­ing solid tumours
• Alter­na­tive scaf­folds and novel anti­body formats

Day 2 Stream 2 – Pro­tein Purifi­ca­tion & Down­stream Processing

• Reduc­ing pro­tein pro­duc­tion time­lines with cell line devel­op­ment and novel dis­pos­able technologies
• Obtain­ing ref­er­ence stan­dards for ther­a­peu­tic proteins
• Pro­tein sta­bil­ity in phar­ma­ceu­ti­cal manufacturing:
  • stor­age concerns
  • extend­ing ‘shelf life’
• Automa­tion and robot­ics to enhance processing

We will require:

• Poster title, Abstract (200 words or less)
• Prin­ci­pal author, Organ­i­sa­tion, Mail­ing address
• Email, Tele­phone, Fax
• Addi­tional authors

In order to secure your board space a fee of £250 plus VAT will be required. The poster should be pre­sented as A0 (841mm x 1189mm) por­trait size. To take advan­tage of this oppor­tu­nity you need to be reg­is­tered as a paid del­e­gate over the 2 days. We have lim­ited spaces avail­able, so please book soon!